Papillomavirus prophylactic vaccines: Established successes, new approaches

M. Saveria Campo, Richard B.S. Roden

Research output: Contribution to journalShort surveypeer-review


Vaccines against the human papillomaviruses (HPVs) most frequently associated with cancer of the cervix are now available. These prophylactic vaccines, based on virus-like particles (VLPs), are extremely effective, providing protection from infection in almost 100% of cases. However, the vaccines present some limitations: they are effective primarily against the HPV type present in the vaccine, are expensive to produce, and need a cold chain. Vaccines based on the minor capsid protein L2 have been very successful in animal models and have been shown to provide a good level of protection against different papillomavirus types. The potential of L2-based vaccines to protect against many types of HPVs is discussed.

Original languageEnglish (US)
Pages (from-to)1214-1220
Number of pages7
JournalJournal of virology
Issue number3
StatePublished - Feb 2010

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Insect Science
  • Virology


Dive into the research topics of 'Papillomavirus prophylactic vaccines: Established successes, new approaches'. Together they form a unique fingerprint.

Cite this